NervGen Pharma Corp. (NGEN)
| Market Cap | 302.68M +97.6% |
| Revenue (ttm) | n/a |
| Net Income | -32.18M |
| EPS | -0.44 |
| Shares Out | 80.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,800 |
| Open | 3.800 |
| Previous Close | 3.830 |
| Day's Range | 3.693 - 3.871 |
| 52-Week Range | 1.500 - 6.300 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+381.28%) |
| Earnings Date | May 22, 2026 |
About NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Co... [Read more]
Analyst Summary
According to one analyst, the rating for NGEN stock is "Strong Buy" and the 12-month stock price target is $18.0.
News
NervGen Pharma appoints Keith Vendola as CFO
NervGen announced the appointment of Keith Vendola as CFO, effective immediately. Vendola will lead the company’s financial strategy and operations, including capital markets activity, financial plann...
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company is developing therapies for devastating neurological condition...
NervGen Pharma initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NervGen Pharma (NGEN) with a Buy rating and $18 price target The company’s lead clinical candidate, NVG-291, is about to enter a pivotal trial for…
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma price target raised to $12 from $10 at Maxim
Maxim raised the firm’s price target on NervGen Pharma (NGEN) to $12 from $10 and keeps a Buy rating on the shares, citing alignment with the FDA on RESTORE, the…
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
NervGen Pharma (NGEN) announced the completion of an End-of-Phase 2 meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for the…
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
VANCOUVER, British Columbia, April 07, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
Stifel lowered the firm’s price target on NervGen Pharma (NGEN) to $5.50 from $6.75 and keeps a Buy rating on the shares after having hosted an update with NervGen’s CEO…
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class n...
NervGen Pharma to delist shares from TSX
NervGen Pharma (NGEN) announced that the company has elected to voluntarily delist its common shares from TSX Venture Exchange, effective at the close of markets on March 16. Published first…
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fir...
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel
Stifel raised the firm’s price target on NervGen Pharma (NGEN) to C$6.75 from C$5 and keeps a Buy rating on the shares.
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
NervGen Pharma (NGEN) appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President, SVP, Patient Advocacy and Clinical Affairs. Most recently, Ruff served ...
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fir...
NervGen Pharma to Participate at Upcoming Investor Conferences
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independenc...
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury
NervGen Pharma Begins Trading on Nasdaq Today
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing firs...
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Foo...
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Par...
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...